Mode
Text Size
Log in / Sign up

Migraine with or without aura

Part of Migraine

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for migraine with or without aura

11 trials tracked for migraine with or without aura: 9 in phase 3 or 4 and 9 with published results. The most-cited published study has 405 citations.

11Trials tracked
9Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 3 9 Phase 2 1 Other / NA 1
  1. Phase 3 Safety and Efficacy in Adult Subjects With Acute Migraines Completed · 405 cited
  2. Phase 3 Trial in Adult Subjects With Acute Migraines Completed · 400 cited
  3. Phase 3 Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention Completed · 233 cited
  4. Phase 3 Safety and Efficacy Study in Adult Subjects With Acute Migraines Completed · 51 cited
  5. Phase 3 Open Label Safety Study in Acute Treatment of Migraine Completed · 45 cited
  6. Phase 3 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Completed · 36 cited
Show 5 more trials
  1. Phase 3 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Completed · 36 cited
  2. Phase 3 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Completed · 26 cited
  3. Phase 3 Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine Completed · 22 cited
  4. Phase 2 The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination Completed
  5. N/A Cooling to Alleviate Migraine #3 Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Migraine with or without aura: what the trials found

Rimegepant has demonstrated statistically significant improvements in acute migraine symptoms at 2 hours post-dose. Specifically, trials showed significantly higher rates of pain freedom compared to placebo across multiple studies [2, 3, 5]. Additionally, Rimegepant was associated with significantly higher rates of freedom from the most bothersome symptom (MBS) and photophobia [2, 5]. One trial also reported a low incidence of liver enzyme elevations (AST/ALT > 3x ULN concurrent with total bilirubin > 2x ULN) during treatment 6.

Ubrogepant demonstrated statistically significant improvements in pain freedom at 2 hours post-dose compared to placebo across two trials [7, 8]. While results for the absence of the most bothersome symptom (MBS) were not statistically significant in one trial 7, they were significantly higher than placebo in another 8. Furthermore, Ubrogepant showed a statistically significant increase in pain relief at 2 hours post-dose compared to placebo 8.

Atogepant demonstrated a statistically significant reduction in mean monthly migraine days (migraine/probable migraine headache days) over a 12-week treatment period 4. It also resulted in a statistically significant reduction in mean monthly headache days during the same period 4. Lasmiditan 50 mg showed statistically significant results for both pain freedom and freedom from the most bothersome symptom at 2 hours post-dose 10.

Recent results — preliminary, needs further review

  • Mi-Helper did not show a statistically significant difference compared to placebo for pain freedom at 2 hours, freedom from most bothersome symptom (MBS) at 2 hours, or sustained pain freedom at 24 hours 1.

For the clinician treating this condition

  • Rimegepant provides statistically significant relief from pain, photophobia, and the most bothersome symptoms within 2 hours of administration [2, 3, 5].
  • Ubrogepant is associated with statistically significant pain freedom and increased pain relief at 2 hours post-dose [7, 8].
  • Atogepant significantly reduces the mean number of monthly migraine days over a 12-week period 4.
  • Lasmiditan 50 mg provides statistically significant relief from both pain and the most bothersome symptoms at 2 hours post-dose 10.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.

Research across Migraine

Related studies from across the Migraine family.

Probiotics provide the largest reduction in migraine frequency among analyzed nutritional supplements
Neurology Meta-analysis
Probiotics provide the largest reduction in migraine frequency among analyzed nutritional supplements Probiotics and Coenzyme Q10 Show Promise for Migraine Frequency
This network meta-analysis of 791 adult migraineurs evaluated vitamins, magnesium, coenzyme Q10, and probiotics. Probiotics showed the large…
New analysis shows that probiotics and coenzyme Q10 may reduce how often migraines occur, while magnesium specifically helps lower pain seve…
Sumatriptan/naproxen sodium and ibuprofen show significant pain freedom for pediatric migraine treatment
Drug Pipeline Meta-analysis
Sumatriptan/naproxen sodium and ibuprofen show significant pain freedom for pediatric migraine treatment New analysis shows effective migraine treatments for children and adolescents
This network meta-analysis of 30 studies involving 8,914 participants evaluated acute migraine medications in children and adolescents. Suma…
A large review of 30 studies helps identify which medications provide the fastest relief from migraines in children and teenagers.
Propranolol shows potential for managing various neurological diseases including PTSD, migraine, and autism spectrum disorder
Psychiatry Sys. Review
Propranolol shows potential for managing various neurological diseases including PTSD, migraine, and autism spectrum disorder Propranolol Shows Promise for Brain Conditions
This systematic review synthesizes clinical and preclinical evidence regarding the effects of propranolol on several neurological conditions…
A new review suggests propranolol, a common blood pressure drug, may help with PTSD, autism, and more. Here's what it means.
Five anchor clinical phenotypes provide a framework for individualized management of persistent postural-perceptual dizziness
Neurology Meta-analysis
Five anchor clinical phenotypes provide a framework for individualized management of persistent postural-perceptual dizziness New framework helps doctors treat persistent postural-perceptual dizziness
This narrative review synthesizes a proposed framework to manage persistent postural-perceptual dizziness (PPPD) by categorizing patients in…
A new clinical framework identifies five distinct types of chronic dizziness to help doctors create personalized treatment plans for patient…
Non-invasive vagus nerve stimulation reduces monthly headache days in migraine patients
Nephrology Meta-analysis
Non-invasive vagus nerve stimulation reduces monthly headache days in migraine patients Trial Shows Vagus Nerve Stimulation Reduces Migraine Frequency
This meta-analysis of 917 patients with migraine found that non-invasive vagus nerve stimulation (nVNS) significantly reduced monthly headac…
Non-invasive vagus nerve stimulation may reduce the number of monthly headache days and the need for acute medication for people living with…
Transcutaneous Vagus Nerve Stimulation utilizes distinct auricular and cervical pathways for non-invasive treatment applications
Neurology Sys. Review
Transcutaneous Vagus Nerve Stimulation utilizes distinct auricular and cervical pathways for non-invasive treatment applications Two different ways to stimulate the vagus nerve for treatment
This narrative review examines the anatomical access points and methodologies for transcutaneous Vagus Nerve Stimulation (tVNS). It distingu…
New research highlights two distinct paths for non-invasive nerve stimulation to treat conditions like migraine and depression.
30% of pediatric patients with migraine report at least one adverse event during pharmacological prophylaxis
Pediatrics Meta-analysis
30% of pediatric patients with migraine report at least one adverse event during pharmacological prophylaxis Trial Shows Specific Side Effects for Children with Migraine
This meta-analysis of 2742 patients evaluates the safety profile of various pharmacological migraine prophylaxis treatments in children and …
About 30% of children and adolescents taking migraine prevention medication report experiencing at least one side effect during treatment.
Migraine patients may have an increased risk of neovascular age-related macular degeneration
Neurology Sys. Review
Migraine patients may have an increased risk of neovascular age-related macular degeneration Migraine patients may face higher risk of certain eye conditions
This narrative review examines the association between migraine and various retinal conditions, including retinal migraine and AMD. The auth…
New research highlights a link between migraines and age-related macular degeneration, potentially impacting long-term vision for many suffe…
Endometriosis genetic risk score tied to pain, cardiometabolic conditions in both sexes
Genetics & Precision Medicine Meta-analysis
Endometriosis genetic risk score tied to pain, cardiometabolic conditions in both sexes Genetic Risk for Endometriosis Linked to Chronic Pain Conditions
This meta-analysis links an endometriosis polygenic risk score (PRS) to 20 of 29 comorbidities in women and to pain and cardiometabolic cond…
A large genetic study reveals that the same genetic markers linked to endometriosis are also associated with fibromyalgia, migraine, and bac…
Neurotological evaluation distinguishes vestibular migraine from viral neuritis in acute unilateral vestibulopathy
ENT (Otolaryngology) Sys. Review
Neurotological evaluation distinguishes vestibular migraine from viral neuritis in acute unilateral vestibulopathy A single case report shows rapid recovery in vestibular migraine
This case report describes a 40-year-old woman with a history of migraine with aura presenting to the emergency department with vestibular m…
A 40-year-old woman with vestibular migraine recovered her balance quickly. This case suggests that specific reflex patterns help doctors te…
Post-marketing data on CGRP inhibitors show paucity of data and additional risks from chronic biologic use
Drug Pipeline Sys. Review
Post-marketing data on CGRP inhibitors show paucity of data and additional risks from chronic biologic use Post-marketing review highlights safety gaps for migraine CGRP drugs
This narrative review examines monoclonal antibodies and Calcitonin Gene-Related Peptide (CGRP) inhibitors for migraine in the post-marketin…
A review of migraine treatments notes limited data on long-term risks for CGRP inhibitors, urging caution during active monitoring.
Asia-Pacific experts reach consensus on migraine management and anti-CGRP mAb use in adolescents
Neurology Guideline
Asia-Pacific experts reach consensus on migraine management and anti-CGRP mAb use in adolescents Asia-Pacific experts find consensus on migraine diagnosis and treatment
This guideline presents a Delphi consensus involving 14 headache specialists from seven Asia-Pacific countries. The group evaluated statemen…
Headache specialists across Asia-Pacific agree on key migraine diagnosis and treatment steps, favoring anti-CGRP drugs for most patients but…